



**FORM PTO-1449 TO BE FILED WITH  
INFORMATION DISCLOSURE STATEMENT**

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.: 183625-4  
Serial No.: 10806358  
Filing Date: 3/19/2004  
Applicant: Harris et al.

INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANTS

**U.S. PATENTS**

Examiner's Initials	Document No.	Date	Name	Class/Sub-Class
<i>UPK</i>	4,473,495	09/24/1984	Patterson	260/112 R

**U.S. PATENT APPLICATIONS**

Examiner's Initials	Document No.	Date	Name	Class/Sub-Class
<i>UPK</i>	US 2002/0090357 A1	07/11/2002	Barrat et al.	424/93.7

**FOREIGN DOCUMENTS**

Examiner's	Document No.	Date	Name
<i>UPK</i>	PCT/IB2004/002124	10/26/2005	Robertson
<i>UPK</i>	W0 2004/035084	04/29/2004	Harris et al.

**OTHER DOCUMENTS**

- UPK* 1. Banga, J. P. et al., Modulation of Antigen Presentation by Autoreactive B Cell Clones Specific for GAD65 from a type I Diabetic Patient, Clinical and Experimental Immunology, Vol. 135, No. 1, January, 2004, pp. 74-84.

UPK 2. Chen Shiow-Ling et al., Responses of NOD Congenic Mice to a Glutamic Acid Decarboxylase-derived Peptide, Journal of Autoimmunity, Vol. 7, No. 5, 1994, pp. 635-641.

UPK 3. DMCCAD: GAD in Metabolic & Neurologic Disease, [http://www.diamyd.com/docs/pdf/GAD\\_IN\\_METABOLIC\\_PD](http://www.diamyd.com/docs/pdf/GAD_IN_METABOLIC_PD), June, 2003.

UPK 4. Patent Abstracts of Japan, Vol. 1997, No. 12, 12/25/97, JP 09 2200092 A.

UPK 5. Endl Josef et al., Identification of Naturally Processed T Cell Epitopes from Glutamic Acid Decarboxylase Presented in the Context of HLA-DR Alleles by T Lymphocytes of Recent Onset IDDM Patients, Journal of Clinical Investigation, Vol. 99, No. 10, 1997, pp. 2405-2415.


UPK 6. Tian Jide et al., T Cell Cross-Reactivity Between Coxsackievirus and Glutamate Decarboxylase is Associated with a Murine Diabetes Susceptibility Allele, Journal of Experimental Medicine, Vol. 180, No. 5, 1994, pp. 1979-1984.

~~7. PCT International Search Report, PCT/IB2005/002135, 08/11/2005.~~

UPK 8. Press Release: Diamyd increases C-peptide levels in diabetes patients with GAD antibodies, online 11/24/2003, [http://222.diamyd.com/docs/PressClip.a.spx?PageID=10&LangID=2&ClipID=210&sm+b\\_b](http://222.diamyd.com/docs/PressClip.a.spx?PageID=10&LangID=2&ClipID=210&sm+b_b), pp. 1-55.

~~9. Diamyd: Halvarssrapport for Diamyd Medical AB, online 05/02/2000, pp. 1-5, <http://di.se/Avdelningar/pressreleaseShow.aspx?pressSeqNo=996&pressCp=1&smallscreen+0&>.~~

- UK 10. Ramiya, V. K. et al., Immunization Therapies in the Prevention of Diabetes, Journal of Autoimmunity, London, GB, Vol. 10, 1997, pages 287-292, XP002918457 abstract.
- UK 11. Christgau, S. et al., Membrane Anchoring of the Autoantigen GAD65 to Microvesicles in Pancreatic Beta-Cells by Palmitoylation in the NH2-Terminal Domain, Journal of Cell Biology, Rockefeller University Press, New York, US, US Vol. 118, No. 2, July 1, 1992, abstract.
- UK 12. Falornia et al., US 6 093 396 A, July 25, 2000 abstract.
- UK 13. Petersen et al., Neonatal Tolerization with Glutamic Acid Decarboxylase but not with Bovine Serum Albumin Delays the Onset of Diabetes in NOD Mice, Diabetes, Vol. 43, No. 12, December, 1994, pp. 1478-1484.
- UK 14. Zimmet et al., Latent Autoimmune Diabetic Mellitus in Adults (LADA): The Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency, Diabetic Medicine, Vol. 11, 1994, pp. 299-303.
- UK 15. Elliott, J. F. et al., Immunization with the Larger Isoform of Mouse Glutamic Acid Decarboxylase (GAD67) Prevents Autoimmune Diabetes in NOD Mice, Diabetes, New York, NY, US, Vol. 43, No. 12, 12/01/1994, pp. 1494-1499.
- UK 16. Tisch, R. et al., Antigen-specific Mediated Suppression of Beta Cell Autoimmunity by Plasmid DNA Vaccination, Journal of Immunology, The Williams and Wilkins Co., Baltimore, US, Vol. 166, No. 3, 02/01/2001., pp. 2122-2132.

Examiner 	Date Considered 1/23/06
--	-------------------------